Nutra Pharma Corp., a biotechnology holding company that owns rights to intellectual property related to the development of drugs for HIV and Multiple Sclerosis has announced that its contract researchers, Eno Research and Development, Inc. (ERDI) have reported early results of its microarray studies with RPI-78M in the gene expression of Multiple Sclerosis (MS) cells. RPI-78M is the lead drug candidate of Nutra Pharma's minority holding, ReceptoPharm, Inc. and is being studied in preclinical assays for its efficacy in treating Multiple Sclerosis. ERDI measured the effect of RPI-78M on gene expression using cDNA microarray technology to identify any potentially unique changes in gene expression that may be caused by the therapy.
With only a few exceptions, every cell of the body contains a full set of chromosomes and identical genes. Only a fraction of these genes are turned on, however, and it is the subset that is "expressed" that confers unique properties to each cell type. "Gene expression" is the term used to describe the transcription of the information contained within the DNA, the repository of genetic information, into messenger RNA (mRNA) molecules that are then translated into the proteins that perform most of the critical functions of cells. Scientists study the kinds and amounts of mRNA produced by a cell to learn which genes are expressed, which in turn provides insights into how the cell responds to its changing needs. Gene expression is a highly complex and tightly regulated process that allows a cell to respond dynamically both to environmental stimuli and to its own changing needs. This mechanism acts as both an "on/off" switch to control which genes are expressed in a cell as well as a "volume control" that increases or decreases the level of expression of particular genes as necessary. Microarrays allow scientists to analyze expression of many genes in a single experiment quickly and efficiently. They represent a major methodological advance and illustrate how the advent of new technologies provides powerful tools for researchers. Scientists are using microarray technology to try to understand fundamental aspects of growth and development as well as to explore the underlying genetic causes of many human diseases.
ERDI was contracted by Nutra Pharma to analyze the cells of MS patients with and without the addition of RPI-78M. They then measured the changes in gene expression that occurred. Preliminary results indicate that the expression level of several genes changed significantly when in the presence of the RPI-78M.
"There are several published studies that examined the gene expression of cells isolated from MS patients," commented James Flowers, President and Chief Scientific Officer of Eno Research and Development, Inc. (ERDI). "Our research aims to identify any potentially unique changes in gene expression that may be caused by therapy with RPI-78M. Although our analysis of the current microarray data is not yet complete, our goal is to determine if the genes affected by the treatment are acting in opposition to the normal patterns of the MS cell. In other words, if a normal MS cell overexpresses a particular gene – does the cell with RPI-78M lower that particular gene's expression?" he continued. "These experiments will not only help us understand the mechanism of action for RPI-78M, they will also prove invaluable in increasing our knowledge of how the disease process of Multiple Sclerosis progresses." ERDI will continue to study RPI-78M and its effects on gene expression as well as the drug's effects in histoculture experiments that may further elucidate its mechanism of action. They are expected to complete these studies by the end of the year.
"These results are very encouraging," commented Rik Deitsch, Chief Executive Officer of Nutra Pharma. "This is further validation of RPI-78M. These studies, when coupled with the positive results in the recently-completed animal model, create substantial evidence of the drug's effects against Multiple Sclerosis. With the near-term completion of the preclinical work by ERDI, we should be able to move into human trials very soon," he added.
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). Early results of microarray studies using RPI-78M should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.